As of Tuesday, February 24, Repligen Corporation’s RGEN share price has dipped by 6.43%, which has investors questioning if ...

If you are wondering whether Repligen at around US$119.99 is a bargain or still looks expensive, you are not alone. That is exactly what this article aims to unpack for you. Over the past week the ...

Shares of the bioprocessing giant Repligen Corporation (NASDAQ: RGEN) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have cooled ...

Repligen (RGEN) is back in focus after a sector wide pullback, with the stock sliding 4.4% as investors reacted to healthcare job losses and fresh scrutiny of the company’s profitability trends. See ...

During the last three months, 5 analysts shared their evaluations of Repligen (NASDAQ:RGEN), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ratings, ...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

Last year demonstrated both the promise and the peril associated with investing in shares of Repligen Corporation. By late May, the bioprocessing leader's stock had doubled. By the end of 2015, most ...